Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sofar S.P.A
Deal Watch: Gemini Goes Through Second Re-Invention Via Reverse Merger With Disc Medicine
Less than two year after going public by a SPAC merger, Gemini will reverse merge with hematology-focused Disc. Bristol Myers Squibb and GentiBio will join forces on Treg development for inflammatory bowel disorders.
Asking For Trouble – Posing A Question Lands Cranberry Supplement In Hot Water With Italian Ad Regulator
An advertisement for a cranberry supplement which asked the question ‘Urinary tract infection?’ earned Italy's Sofar a slap on the wrist from the country's advertising regulator. The authority ruled that posing such a question was misleading consumers about the product's curative qualities.
Keeping Track: Clarus, Agile and Sunovion Look To Bounce Back From CRLs; FDA To Review Rituximab Biosimilar
The latest drug development news and highlights from our US FDA Performance Tracker.
EpiPen Familiarity May Prove Tough Hurdle For Generics
With EpiPen injector patent-protected and patients accustomed to its use, finding a substitutable generic device may prove difficult.
- Medical Devices
- OTC, Consumer
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.